目的 探讨曲美他嗪对冠心病患者胰岛素抵抗的疗效.方法 将我院收治的201例冠心病患者随机分为实验组以及对照组,其中对照组患者采用常规治疗方案进行治疗,实验组患者在对照组基础上加曲美他嗪进行治疗.对两组患者的临床疗效以及血糖、胰岛素分泌等情况进行分析.结果 实验组患者在心绞痛发作频率、心绞痛持续时间以及硝酸甘油的使用情况方面均优于对照组(P<0.05);实验组患者在接受治疗后的胰岛素水平明显低于对照组(P<0.05),而两组患者治疗前后血糖比较差异无统计学意义(P>0.05);对两组患者治疗前后胰岛素敏感指数比较,两组患者在治疗后比较差异有统计学意义(P<0.05).结论 对冠心病患者采用曲美他嗪进行治疗,可降低患者胰岛素抵抗,提高患者临床疗效.%Objective To investigate efficacy of insulin resistance in patients with coronary heart disease (CHD) treated by Trimetazidine. Methods 201 cases of CHD patients admitted to our hospital were divided into experimental group and control group in random. Patients in control group were given conventional treatment, while in experimental group, they were added with Trimetazidine besides conventional treatment. The clinical efficacy, blood sugar, and insulin secretion were analyzed in both groups. Results The indications of frequency of attack, lasting time, and nitroglycerin taking in anginal patients in experimental group were superior to those of control group (P ＜ 0.05). Insulin level for patients after receiving Trimetazidine was obviously lower than that of control group (P ＜ 0.05), while blood sugar level before and after treatment in both groups had no significant difference (P ＞ 0.05). Insulin sensitivity index before and after treatment showed a statistical difference in the two groups (P ＜ 0.05). Conclusion Trimetazidine added to CHD patients can reduce their insulin resistance and improve clinical effects.
展开▼
